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Abstract  
To date, surgical interventions are the only means by which craniofacial anomalies can be 
corrected so that function, esthetics, and the sense of well-being are restored in affected 
individuals. Unfortunately, for patients with cleft palate—one of the most common of congenital 
birth defects—treatment following surgery is prolonged over a lifetime and often involves 
multidisciplinary regimens. Hence, there is a need to understand the molecular pathways that 
control palatogenesis and to translate such information for the development of noninvasive 
therapies that can either prevent or correct cleft palates in humans. Here, we use the well 
characterized model of the Pax9−/− mouse, which displays a consistent phenotype of a 
secondary cleft palate, to test a novel therapeutic. Specifically, we demonstrate that the 
controlled intravenous delivery of a novel mouse monoclonal antibody replacement therapy, 
which acts as an agonist for the ectodysplasin (Eda) pathway, can resolve cleft palate defects in 
Pax9−/− embryos in utero. Such pharmacological interventions did not reverse the arrest in 
tooth, thymus, and parathyroid gland development, suggesting that the relationship of Pax9 to 
the Eda/Edar pathway is both unique and essential for palatogenesis. Expression analyses and 
unbiased gene expression profiling studies offer a molecular explanation for the resolution of 
palatal defects, showing that Eda and Edar-related genes are expressed in normal palatal 
tissues and that the Eda/Edar signaling pathway is downstream of Pax9 in palatogenesis. 
Taken together, our data uncover a unique relationship between Pax9 and the Eda/Edar 
signaling pathway that can be further exploited for the development of noninvasive, safe, and 
effective therapies for the treatment of cleft palate conditions and other single-gene disorders 
affecting the craniofacial complex. 
Keywords: Developmental biology, Cleft palate, craniofacial biology/genetics, morphogenesis, 
gene expression, therapeutic treatment. 
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Introduction  
Disruptions in craniofacial development lead to a spectrum of malformations that comprise 
over one-third of all congenital birth defects and often lead to devastating clinical and 
psychosocial consequences. Most of these disorders involve mineralizing tissues, such as the 
cranial and facial sutures, the palate and tooth organs, as well as the maxilla and mandible 
(Szabo- Rogers et al. 2010; Twigg and Wilkie 2015). Despite the advances made in our 
understanding of the genetic etiology and mechanisms responsible for these conditions, 
treatment options are restricted to surgical interventions that, if successful, require life-long care. 
Hence, there is a critical need to develop novel therapies that are biologically driven, minimally 
invasive, safe, and effective. 
Classified as the most common among craniofacial disorders are clefts of the palate and lip, 
which occur in 1 per 700 live births worldwide and present with a heterogenous etiology 
involving both genetic and environmental risk factors (Mossey et al. 2009; Dixon et al. 2011; 
Leslie and Marazita 2013; Beaty et al. 2016). Significant progress has been made in unraveling 
the causes of syndromic and nonsyndromic (isolated) forms of cleft palate using a combination 
of analytical approaches: whole genome sequencing, whole-exome sequencing, genome-wide 
association analyses, and carefully executed epidemiologic and phenotypic characterization 
studies (Beaty et al. 2016; Leslie and Marazita 2013). Furthermore, studies of genetically 
engineered mice with cleft palate phenotypes have underscored the importance of the 
transforming growth factor (TGF)-β, fibroblast growth factor (FGF), WNT, hedgehog, and 
mitogen activated protein kinase (MAPK) signaling pathways in palatogenesis (Funato et al. 
2015). Among the 180 mouse cleft genes identified through gene ontology analyses, 
transcription factors, particularly those with homeobox-containing domains, are the most 
significantly enriched in palatogenesis (Funato et al. 2015). This improved understanding of the 
mechanisms that drive normal and abnormal palatogenesis and the array of diagnostic tools 
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readily available provide opportunities to prevent or reverse palatal defects in a manner that will 
reduce morbidity and mortality, obviate the need for surgery, and reduce patient 
dependence on life-long multidisciplinary care. 
Pax9 is known to play a key role in palatogenesis and in the development of tooth organs 
and other pharyngeal pouch derivatives. Its deficiency consistently leads to cleft of the 
secondary palate, along with arrests in tooth, thymus, and parathyroid gland development 
(Peters et al. 1998). Studies by Zhou et al. (2013) point to a role for Pax9 in the patterning of 
the anterior-posterior (AP) axis and palatal shelf outgrowth through its control of cell proliferation 
and its interactions with the Bmp, Fgf, and Shh pathways (Zhou et al. 2013). 
However, there is much to learn about the relationship between Pax9 and other signaling 
pathways during palatogenesis. Our recent studies have shown that Pax9 shares an upstream 
molecular relationship with Wnt pathway genes during palate formation (unpublished data). Wnt 
genes encode a family of secreted signaling proteins that regulate developmental processes 
critical for palatogenesis, such as early patterning, cell proliferation, differentiation, and 
apoptosis. Several reports confirm that Wnt signaling is linked with the ectodysplasin/ 
ectodysplasin A receptor (Eda/Edar) pathway during hair follicle, tooth, and mammary gland 
development (Laurikkala et al. 2001; Zhang et al. 2009; Voutilainen et al. 2015). Since Pax9 is 
involved with Wnt signaling during palatogenesis, the focus of this study was to evaluate 
whether the Eda/Edar signaling pathway is involved with Pax9 during palate formation and 
whether such a relationship could be exploited for pharmacological interventions aimed at 
correcting palatal defects in Pax9−/− mice. 
Our approaches have been inspired by the successes of using recombinant EDA (rEDA) 
protein for the treatment of X-linked hypohidrotic ectodermal dysplasia (XL-HED), a syndrome 
caused by mutations in the EDA gene, which encodes a ligand in the tumor necrosis factor 
(TNF)/EDA signaling pathway. XL-HED is characterized by a failure of hair, tooth, and 
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gland development (Monreal et al. 1998). A few timely injections of rEDA protein can correct all 
XL-HED defects in Eda-deficient Tabby mice permanently (Gaide and Schneider 2003). Both 
rEDA protein and an agonist EDA-receptor monoclonal antibody (mAbEDAR) are capable of 
permanently correcting the dental phenotypes of XL-HED in mice and especially dogs, with the 
rescue of permanent dentition following EDA treatment in early postnatal life (Casal et al. 1997; 
Kowalczyk et al. 2011; Mauldin et al. 2009). 
The results of our expression and molecular analyses demonstrate for the first time that 
Pax9 shares an upstream molecular relationship with the Eda/Edar signaling pathway during in 
vivo palatogenesis. The importance of these interactions is underscored by our findings that an 
agonist anti-EDAR monoclonal antibody, when administered in utero, reverted secondary palate 
clefts in Pax9−/− mouse embryos. Taken together, these data advance our knowledge about 
palatogenesis and help to explain the mechanism underlying the resolution of the cleft defects in 
Pax9−/− mice. 
 
Materials and methods 
Mouse Strains and Tissues 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Utah (Protocol #17-02004). Breeding pairs of Pax9+/− 
mice were provided by Dr. Rulang Jiang (Cincinnati Children’s Hospital; Zhou et al. 2011) and 
maintained on a C57BL/6 background with 2- to 8-month-old females for intercross mating. 
Whole heads were obtained from NF-B-LacZ reporter mice staged from E12.5 to E15.5 and 
staining for beta-galactosidase activity was performed as described by Bhakar et al. (2002). 
Expression and Activity Studies 
In situ hybridizations were performed using digoxigenin-labeled RNA probes to Eda, Edar 
and Col1a1, as described previously (D’Souza et al. 1993; Zhang et al. 1999; Zhou et al. 2013). 
For whole-mount in situ hybridization, a 2 μg/ml antisense RNA probe was loaded onto each 
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sample, and an antidigoxigenin-AP antibody (11093274910, Roche, 1:2,000) was used to detect 
the labeled probe. For section in situ hybridization, a 1 μg/ml antisense RNA probe was loaded 
onto each position-matched section and anti-digoxigenin-AP antibody (1:1,000) was used to 
detect the labeled probe. Comparable images were taken by digital microscope (EVOS). At 
least 5 replicates were performed for each assay. For whole-mount X-gal staining of Eda/Edar 
signaling activity, the whole heads of NF-κB reporter embryos from E12.5 to E15 were fixed in 
4% paraformaldehyde after removal of the lower jaw, then treated as previously described 
(Voutilainen et al. 2015). 
Delivery of mAbEDAR monoclonal antibody and histological analysis  
The anti-EDAR monoclonal antibody 1 (hereafter referred to as mAbEDAR) was injected 
into the tail vein of timed pregnant females, as previously described (Kowalczyk et al. 2011). 
The dosage of 16 mg/kg of body weight was calculated based on a 
half-life (t 1/2) of the antibody estimated to be 10 days. Hence, a single injection at E10.5—one 
day preceding the initiation of palatogenesis—was sufficient to cover critical events that occur 
from E11.5 to E15.5 of embryogenesis. A second injection at E12.5 was delivered to study the 
effects of an extra burst of signaling activity at a time of palatal shelf outgrowth. The same 
amount of bovine serum albumin diluted in phosphate-buffered saline was delivered to the 
controls. Embryos were fixed in 4% paraformaldehyde overnight and serial coronal sections 
were stained with hematoxylin and eosin for morphologic evaluation. Position-matched sections 
were stained with Masson’s trichrome to evaluate connective tissue deposition (Chen et al. 
2009). 
RNAseq and Real-Time RT-PCR analyses 
Whole-transcriptome profiling of the developing palatal shelves was performed by RNA-
Seq and data were collated at the High-Throughput Genomics and Bioinformatics Analysis Core 
Facility (University of Utah). In brief, after total RNAs were extracted from individual samples, 
cDNA libraries were generated using the Illumina TruSeq RNA Sample Prep Kit v2 with oligo(dT) 
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selection (Jia et al. 2013). Read counts were generated using USeq’s Defined Region 
Differential Seq application and normalized counts were used in DESeq2 to measure differential 
expression. The RNA-seq raw data have been deposited into Gene Expression Omnibus 
database (GEO) (http://www.ncbi.nlm.nih.gov/geo) under the accession number, GSE89603. 
For real-time RT-PCR, first-strand cDNA was synthesized using the SuperScript First-Strand 
Synthesis System (Thermo Fisher Scientific). Quantitative PCRs were performed in a 
StepOnePlus Real Time RT-PCR System (Applied Biosystems) using the SYBR Green qPCR 
Supermix (Thermo Fisher Scientific). The list of primer sets is provided in Appendix Table 1. 
Five sets of samples were analyzed for each gene, and a Student’s t-test was used to analyze 
differences, with P values of <0.01 considered statistically significant. 
 
Results 
Pax9 shares a molecular relationship with the Eda/Edar signaling pathway during 
palatogenesis 
Since the expression of Eda/Edar pathway genes has not been studied in normal and 
Pax9−/−palatal shelves, we first examined the differential expression of Eda/Edar genes in 
these tissues. Comparing the unbiased set of RNAseq data obtained from dissected Pax9+/+ 
and Pax9−/− E13.5 palatal shelves, we determined normalized raw counts for each of the 
Eda/Edar signaling pathway-related genes. As shown in Fig. 1A, the expression of Edar was 
significantly reduced in Pax9−/−samples (P < 0.01). The 2-fold reduced expression level of Edar 
in Pax9−/−palate was confirmed by real-time RT-PCR (Fig. 1B). 
To better assess the function of the Eda/Edar signaling pathway in palatogenesis, we 
analyzed Eda/Edar signaling activity during palate formation using NF-B reporter mice. The 
transcription factor, NF-B, is a downstream mediator of Eda/Edar signaling. As Appendix Fig. 1 
shows, NF-B activity in the palate was lost in Eda−/− background, confirming that the reporter 
expression is a reliable indicator of Eda/Edar signaling activity during palatogenesis. We 
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analyzed Eda/Edar signaling activity using NF-B reporter embryos staged from E12.5 to E15 
(Fig. 2A–D). X-gal wholemount staining showed that, at E12.5, the domain of NF-B activity 
started to appear at the center of the lingual edge (Fig. 2A) and extended along the edge of 
palate at E13 (Fig. 2B). At E14, the activities appeared throughout the lingual edge of the palate 
and on the palatal rugae (Fig. 2C). After palate fusion at E15, lac Z staining was only retained 
on the rugae (Fig. 2D). These results indicate that Eda/Edar signaling is active during 
palatogenesis, and that the activity is affected in Pax9−/−samples. 
Compared with NF-kB activity, whole-mount in situ hybridization showed that endogenous 
Edar mRNA transcripts had a broader expression, with higher expression seen in the lingual 
region and lower expression in the buccal region of the developing Pax9+/− palate shelves (Fig. 
2E, I). The lingual expression domain for Edar transcripts appeared to be reduced in Pax9−/− 
palatal shelves (Fig. 2F, J). Interestingly, Eda showed a lingual–buccal gradient of expression at 
E13.5, with the domain of expression becoming restricted to the lingual region of the posterior 
palatal shelves at E14.5 (Fig. 2G, K). In Pax9−/−palates, Eda expression resembled that seen in 
Pax9+/− shelves at E13.5 but was far more diffuse at E14.5 (Fig. 2H, L). 
 
Treatments using mAbEDAR reverse cleft palate defects in Pax9-/- mice. 
The agonist monoclonal antibody mAbEDAR, when administered in a timely manner to 
mice and dogs, serves as an effective pharmacological intervention for XLHED (Kowalczyk et al. 
2011). Here, we delivered 16 mg/kg/body weight of mAbEDAR to Pax9−/− embryos through tail 
vein injection of timed pregnant Pax9+/−female mice (Fig. 3A). A single injection administered at 
E10.5 resulted in a 71.4% success rate of secondary palate closure (10/14 Pax9−/− embryos) 
(Fig. 3B). The second delivery schedule, comprising 2 separate injections at E10.5 and E12.5, 
resulted in 90% closure of secondary palate defects (9/10 Pax9−/−embryos) (Fig. 3B). 
Stereoscope evaluation of palates from mAbEDAR-treated samples showed that palatal shelf 
fusion had occurred in the midline after mAbEDAR treatments (Fig. 4C). Whereas mAbEDAR 
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therapy resulted in closure of the secondary palate, the morphology of the rugae did not appear 
to be fully restored (Fig. 4C). In comparison, Pax9+/+ embryos from control litters that did not 
receive mAbEDAR showed closed palates with parallel morphology of rugae (Fig. 4A). 
Pax9−/−embryos from control treatment litters showed complete cleft secondary palates, as 
shown in Fig. 4B. 
We observed residual defects in 4 of 10 Pax9−/− embryos derived from litters that 
received a single injection of mAbEDAR and in 3 of 9 mutant embryos from litters treated with 2 
injections of mAbEDAR. As shown in Appendix Fig. 2C, these residual defects were clearly 
visible in fusion zones between primary and secondary palates. Histological evaluation of 
position-matched, hematoxylin- and eosin-stained coronal sections of E18.5 embryos, showed 
normal palate fusion in wildtype controls (Fig. 4D) whereas the palate clefts of Pax9−/− controls 
showed no correction (Fig. 4E). Pax9−/− palate shelves exposed to mAbEDAR were fused in 
the midline region (Fig. 4F). The correction of secondary palate clefts in Pax9−/− mice did not 
prolong their survival after birth and the arrests in tooth, thymus, parathyroid glands, and hind 
limb development were not reversed after mAbEDAR treatment. Importantly, histopathologic 
and MRI analyses of Pax9+/− mothers and siblings exposed to mAbEDAR showed no long-term 
adverse effects on major organ systems (data not shown). 
 
Therapeutic treatments with mAbEDAR result in osteogenesis of the palatal shelves.   
We next confirmed that the effects of mAbEDAR therapy culminate in palatal 
osteogenesis and subsequent fusion, and was not limited to soft tissue apposition alone, as has 
been reported for submucosal cleft palates, a clinical phenotype described in the literature 
(Weatherley-White et al. 1972; Garcia Velasco et al. 1988;). We compared Masson’s trichrome 
staining patterns with that of type I collagen (Col1a1) mRNA expression in experimental and 
control groups. Masson’s trichrome observed in mAbEDAR-treated Pax9−/− tissues closely 
resembled that in Pax9+/− tissues, and indicated newly deposited connective tissue (blue color) 
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in both the anterior and posterior zones of the palate (Fig. 5 A–F). Positive expression of Col1a1, 
a marker of differentiated osteoblasts, is indicative of active osteogenic zones within palatal 
shelves in treated Pax9+/− embryos (Fig. 5G, J). In contrast, untreated Pax9−/− samples failed 
to show Col1a1 expression within the stunted palatal shelf mesenchyme (Fig. 5H, K). After 
mAbEDAR monoclonal antibody treatment, true fusion of the secondary palate was evident, as 
shown by Col1a1 expression in osteoblasts present within the anterior and posterior zones of 
the palatal shelves (Fig. 5I, L). 
 
Discussion 
Our studies demonstrate for the first time that the Eda/Edar signaling pathway of genes 
mediate the function of Pax9 in murine palatogenesis. Of significance, is the fidelity with which 
the controlled intravenous delivery of mAbEDAR—a mouse agonist anti-EDAR monoclonal 
antibody—can activate endogenous EDAR. Data from our unbiased studies of gene expression 
profiles in whole Pax9−/− palatal shelves using RNA-Seq and real-time PCR analyses showed 
that Pax9 deficiency leads to a 2-fold down-regulation of Edar, the only receptor that binds Eda1 
(the longest and only isoform of Eda critically involved in morphogenesis). Thus, the corrective 
actions of mAbEDAR can be explained by its ability to counteract the effect of reduced EDAR 
expression caused by the absence of Pax9. This conclusion is supported by the findings that 
the size of the sebaceous glands and the amount of sebum secretion in Eda-deficient animals 
exceeds that of the wildtype littermates receiving identical doses of mABEDAR1 (Kowalczyk-
Quintas et al. 2015). Hence, EDAR activity in Pax9−/− mice treated with mAbEDAR can restore 
Eda signaling to functional levels and result in closure of the palatal shelves, as shown by the 
outgrowth of the palatal shelves and bone deposition toward the midline. These findings provide 
compelling in vivo evidence that Pax9 shares an upstream relationship with the Eda/Edar 
signaling pathway. 
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Our expression analyses reveal that NF-B reporter gene expression in the forming 
palate is temporally and spatially regulated. Edar mRNA transcripts appear restricted to the 
lingual domain of the palatal shelves, and are less abundant in the developing palate. 
Interestingly, Eda mRNA transcripts appear more spatially diffuse in the palatal shelves; 
although, the levels of expression were not drastically altered in the absence of Pax9. Taken 
together, these studies describe a unique relationship between Pax9 and the Eda/Edar 
signaling pathway in palatogenesis while offering a new approach for the treatment of cleft 
palate defects in utero. 
Pax9 is important for the patterning of the AP axis during murine palatogenesis and its 
interactions with the Bmp, Fgf and Shh pathways stimulate cell proliferation and the subsequent 
of the palatal shelves (Peters et al. 1998; Zhou et al. 2013). More recently, our research group 
has shown that the Wnt genes are key mediators of Pax9 function in the posterior domain of 
palatal mesenchyme (unpublished data). During the formation of ectodermal appendages, like 
hair follicles and tooth organs, there is a strong interdependence between Wnt and Eda/Edar 
signaling pathways (Laurikkala et al. 2001; Zhang et al. 2009). Such a complex interplay 
between these 2 pathways is also evident in mammary gland bud development, where Wnt 
genes are transcriptional targets of Eda/Edar signaling (Voutilainen et al. 2015). 
Hence, Eda/Edar signaling is also needed for the development of organs other than 
ectodermal appendages, suggesting a broader role for this pathway in organogenesis. Since the 
Eda/Edar system is an important effector of canonical Wnt signaling in developing skin 
appendages, future studies must delineate whether Pax9 shares a direct molecular relationship 
with the Eda/Edar signaling pathway during palatogenesis or whether its actions are mediated 
via Wnt genes. 
Our studies show that agonist anti-EDAR antibodies can correct cleft defects in 
Pax9−/−embryos. However, downless mice harboring a spontaneous missense mutation in 
Edar had defective ectodermal organs and disordered patterns of rugae without cleft palate 
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defects (Headon and Overbeek 1999; Laurikkala et al. 2002). Clefts of the secondary palate are 
also not observed in Edadeficient dogs (Casal et al. 1997) and mutations in EDA genes have 
not yet been associated with cleft palate/lip defects in humans. If the overstimulation of Edar 
with agonists would compensate for the loss of one or several other Pax9 targets, for example 
Wnts, which have been shown to act both upstream and downstream of Edar (Zhang et al. 2009; 
Laurikkala et al. 2001), this could explain why Eda/Edar signaling is dispensable for palate 
formation yet able to substitute for the functions of Pax9 in palatogenesis. 
The availability of pharmacological activators of the Eda/ Edar pathway has advanced 
treatment strategies for the correction of specific XLHED symptoms in humans (Dr. Holm 
Schneider, personal communications). As reviewed by Kowalczyk-Quintas and Schneider 
(2014), Eda-deficiency in animal models can be corrected by the controlled delivery of soluble 
EDAR agonists that precisely target affected ectodermal appendages and lead to the 
permanent correction of adverse phenotypes affecting hair, sweat glands, and tooth organs. 
Because of their long half-life after injection in vivo, agonist anti-EDAR mouse monoclonal 
antibodies are safe and effective in mice, with no signs of neutralizing immune response 
(Kowalczyk et al. 2011), even after chronic administration for months (Kowalczyk-Quintas et al. 
2015). Furthermore, expression levels of Bmp4, Msx1, and Osr2, which are significantly 
downregulated in the absence of Pax9, are not restored after treatment with mAbEDAR 
(Appendix Fig. 3 and 4). This suggests that the signaling hierarchy involving Pax9 and the 
Eda/Edar pathway, while critical for a palate formation, may not involve these molecules. In 
these studies, it is intriguing that mAbEDAR therapy failed to correct other Pax9−/− defects, 
such as arrests in tooth, thymus, and parathyroid gland development (data not shown). 
Correction of other organ defects caused by Pax9 deficiency may therefore require a different 
dosage and/or delivery schedules of mAbEDAR. 
In summary, our studies offer fresh molecular insight into the relationship between Pax9 
and the Eda/Edar signaling pathway during murine palatogenesis. The use of an antibody 
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agonist therapy that targets the Eda/Edar pathway to specifically reverse secondary palate 
clefts in Pax9−/−mice offers promise for future translational studies. Such an approach and 
other strategies can test the use of pharmacologic modulators of key signaling pathways for the 
treatment of other human single-gene disorders of the craniofacial complex. 
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Figure Legends 
Figure 1. Expression profiles of Eda/Edar signaling pathway-related genes in E13.5 palatal 
shelves. 
   
(A) Table of RNAseq data showing raw counts of Eda/Edar signaling pathway-related genes 
selected from RNAseq data. Compared with Pax9+/+ samples, Edar expression was 
significantly downregulated in Pax9−/−samples. FC, fold change; *P < 0.01. 
(B) The mRNA levels were confirmed by real-time RT-PCR (n = 5). Error bars indicate SEM, *P 
< 0.01. 
 
Figure 2. NF-κB activity and Eda/Edar signaling during palate formation.  
(A–D) LacZ staining of NF-κB reporter (rep) embryos from E12.5 to E15. 
Signals appeared at the center of the lingual edge of the palate at E12.5 (A). At E13, the signals 
elongated along the palatal edge (B). At E14, the signals were on the rugae and throughout the 
lingual edge of the palate (C). At E15, the palatal shelves fused and the signals remained on the 
rugae (D). 
(E–L) Comparison of the expression of Edar and Eda mRNAs in the palatal shelves of 
Pax9−/−and Pax9+/− embryos. Whole-mount in situ hybridization of Edar at E13.5 (E, F) and 
E14.5 (I, J). Pax9−/−embryos (E, I) showed strong expression along the lingual region of the 
developing palate shelves (red arrow heads) and incisor tooth germs (red *), whereas Pax9−/− 
embryos (F, J) showed decreased expression levels in both palate shelves and incisors. 
Whole-mount in-situ hybridization of Eda at E13.5 (G, H) showed similar expression level in 
Pax9+/− (G) and Pax9−/−embryos (H). At E14.5 (K, L), Eda had a specific expression in the 
lingual region of the posterior palate in Pax9+/− (K, black arrows), and this pattern was diffused 
in Pax9−/− (L). * indicates incisor tooth germ; red arrowheads indicate lingual region of palate 
shelves; black arrows indicate posterior palate. Scale bar, 100 μm. 
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Figure 3. Treatment with mAbEDAR monoclonal antibody corrected cleft palate defects in 
Pax9−/− embryos. 
(A) Schematic diagram showing the delivery timeline of mAbEDAR monoclonal antibodies. a, 
single injection at E10.5; b, 2 injections at E10.5 and E12.5. 
(B) Table summarizes secondary palate closure with mAbEDAR monoclonal antibody treatment 
in Pax9−/− embryos. *, number of Pax9−/− embryos with incomplete fusion between the primary 
and secondary palates (see Appendix Fig. 2).  
 
Figure 4. Secondary palate fusion in Pax9−/− embryos after mAbEDAR monoclonal antibody 
treatments. 
Representative photographs of palate formation at E18.5 in control treated Pax9+/+ (A, D), 
Pax9−/− (B, E) and mAbEDAR monoclonal antibody treated Pax9−/− (C, F) with the injection 
timeline at E10.5. The whole-mount oral view of palatal shelf showed cleft palates in control 
Pax9−/− embryos (n = 10) (B) and palate closure with disordered rugae in mAbEDAR 
monoclonal antibody treated Pax9-/- embryos (n = 19) (C). Hematoxylin and eosin-stained (D-F) 
coronal sections showed fusion of the palatal shelves in control Pax9+/+ (D) and mAbEDAR 
monoclonal antibody treated Pax9−/− (F) embryos. * indicates cleft palate; black arrows indicate 
secondary palate fusion after treatment; T, tongue; arrowheads indicate intact palate shelve. 
Scale bars, 100 μm. 
 
Figure 5. Restored osteogenesis in the palate of E18.5 Pax9−/− mice treated with mAbEDAR 
monoclonal antibody. 
   
Masson’s trichrome staining (A–F) of coronal sections showed that the palatal shelves were 
fused in control Pax9+/+ (A, D) and mAbEDAR monoclonal antibod-treated Pax9−/− (C, F), 
whereas complete cleft was found in control Pax9−/− (B, E). Connective tissue is stained blue, 
nuclei are dark red/purple, and the cytoplasm is red/pink. (G–L) Comparison of Col1a1 
expression in the palatal bone formation of Pax9+/− and Pax9−/− embryos with mAbEDAR 
monoclonal antibody treatment v. control. Position-matched coronal sections of E18.5 embryos 
through the anterior and posterior palates are used. mRNA signals are shown in blue. The red 
arrow indicates osteogenic centers of the developing palatal processes of the maxilla; the red 
arrowheads indicate prospective palatal processes of the palatine bone. A high-powered view of 
palatal fusion zones is shown in black rectangle boxes. 
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Supplementary Table S1. Primers for Real-time RT-PCR: 
Name Sequence (5’-3’) 
Edar-QF ACAGTCAAGAGCGAGTTCCC 
Edar-QR AGTACACCTGGTACCCGAAT 
Eda-QF AGGTGGAGTGCTCAATGACTG 
Eda-QR CGATTTTCTGCCTGGCCTTG 
GAPDH-QF TGGAGCCAAAAGGGTCA 
GAPDH-QR CTTCTGGGTGGCAGTGA 

